Unreamed Intramedullary Tibial Nailing in Treatment of Open IIIa Diaphyseal Tibial Fractures in Adults
Launched by ASSIUT UNIVERSITY · Feb 26, 2024
Trial Information
Current as of November 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a specific treatment for adults with a type of broken leg called a grade IIIa diaphyseal tibial fracture, which is a severe open fracture of the shin bone (tibia). The main goal is to see how well a method called "unreamed intramedullary nailing" works in helping these fractures heal without complications. The study also aims to find out how often people experience problems after the treatment and how well they can function afterward.
To participate in this trial, you need to have one of these specific fractures and be an adult who has finished growing. Unfortunately, if your fracture is infected or if you have other serious fractures in your knee or ankle area, you won't be eligible for this study. If you join, you can expect to be monitored closely as researchers gather information on how well the treatment works and how it affects your recovery. The trial is not yet recruiting participants, so it's still in the planning stages.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Open grade IIIa diaphyseal tibial fractures .
- • 2. Skeletaly mature patients .
- Exclusion Criteria:
- • 1. late presentation and open infected fractures .
- • 2. Associated intraarticular fractures of proximal /distal tibia.
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported